Health Care • Biotechnology: Pharmaceutical Preparations
$1.54 ▼ -0.39
(-20.21%)
MKT CAP: $7.7M • VOL: 981.0K
52W L $1 52W H $18
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
UPC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $17.86B | $23.02B | $32.31B |
| YoY Revenue Growth % | -22.4% | -28.7% | — |
| Gross Profit | $6.30B | $6.07B | — |
| Gross Margin % | 35.3% | 26.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.92B | -$8.02B | -$3.97B |
| Operating Margin % | -16.3% | -34.8% | -12.3% |
| Net Income (GAAP) | -$3.67B | -$8.73B | -$6.58B |
| EBITDA (Normalized) | -$2.70B | -$7.85B | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.05B | -$9.51B | $1.12B |
| Capital Expenditures (CapEx) | $266.8M | $208.3M | — |
| Free Cash Flow (FCF) | -$5.32B | -$9.72B | $1.12B |
| FCF Margin % | -29.8% | -42.2% | 3.5% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR UPC.